

Rachel Perret

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7767579/publications.pdf>

Version: 2024-02-01

13
papers

643
citations

1040056

9
h-index

1372567

10
g-index

13
all docs

13
docs citations

13
times ranked

1362
citing authors

#	ARTICLE	IF	CITATIONS
1	T-cell intrinsic Toll-like receptor signaling: implications for cancer immunotherapy and CAR T-cells. , 2021, 9, e003065.		30
2	iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine. , 2014, 2, 39.		16
3	CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses. Cancer Immunology, Immunotherapy, 2013, 62, 747-760.	4.2	34
4	Adjuvants That Improve the Ratio of Antigen-Specific Effector to Regulatory T Cells Enhance Tumor Immunity. Cancer Research, 2013, 73, 6597-6608.	0.9	86
5	MicroRNA-155 Is Required for Effector CD8+ T Cell Responses to Virus Infection and Cancer. Immunity, 2013, 38, 742-753.	14.3	278
6	Peptide and Protein-Based Cancer Vaccines. , 2013, , 111-146.		2
7	Inefficient boosting of antitumor CD8+ T cells by dendritic-cell vaccines is rescued by restricting T-cell cytotoxic functions. Oncoimmunology, 2012, 1, 1507-1516.	4.6	6
8	Saponins from the Spanish saffron <i>Crocus sativus</i> are efficient adjuvants for protein-based vaccines. Vaccine, 2012, 30, 388-397.	3.8	19
9	Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. European Journal of Immunology, 2011, 41, 2217-2228.	2.9	69
10	Effector CD8 ⁺ T cells activated <i>in vitro</i> confer immediate and long-term tumor protection <i>in vivo</i> . European Journal of Immunology, 2008, 38, 2886-2895.	2.9	14
11	Virus-like particles from rabbit hemorrhagic disease virus can induce an anti-tumor response. Vaccine, 2008, 26, 5334-5337.	3.8	34
12	Dendritic Cells Treated with Lipopolysaccharide Up-Regulate Serine Protease Inhibitor 6 and Remain Sensitive to Killing by Cytotoxic T Lymphocytes <i>In Vivo</i> . Journal of Immunology, 2008, 181, 8356-8362.	0.8	19
13	Effector lymphoid tissue and its crucial role in protective immunity. Trends in Immunology, 2005, 26, 242-247.	6.8	36